Thymalfasin (Thymosin alpha 1, Ta1)

DRUG4 trials

Sponsors

SciClone Pharmaceuticals, The Methodist Hospital Research Institute, Beijing Friendship Hospital

Conditions

COVID-19 VaccineEGFR Mutation Positive Non Small Cell Lung CancerImmune Response to Covid 19 VaccinationMCRCNon-Small Cell Lung CancerVaccine Response

Phase 1

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone PharmaceuticalsEGFR Mutation Positive Non Small Cell Lung Cancer

Start: 2016-10-31End: 2020-01-31Target: 188Updated: 2016-09-19

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

RecruitingNCT06821100

The Methodist Hospital Research InstituteCOVID-19 Vaccine, Immune Response to Covid 19 Vaccination, Vaccine Response

Start: 2024-12-02End: 2026-12-01Target: 75Updated: 2025-07-31

Phase 2

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone PharmaceuticalsNon-Small Cell Lung Cancer

Start: 2016-09-30End: 2019-07-31Target: 140Updated: 2016-09-19

Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer

RecruitingNCT06829355

Beijing Friendship HospitalMCRC

Start: 2025-02-11End: 2027-12-31Target: 52Updated: 2025-02-17